30 Sep Why PLL Therapeutics chose Australia to launch its phase I/II clinical trial
Read our article in Clinical Leader on ‘Long-distance rare disease trials: Why PLL landed on Australia and New Zealand’:...
Read our article in Clinical Leader on ‘Long-distance rare disease trials: Why PLL landed on Australia and New Zealand’:...
An exclusive interview in International Clinical Trials © Samedan Ltd with our CEO Jean Pascal Zambaux provides insights on the growing evidence of linking the gut-brain axis to Amyotrophic Lateral Sclerosis (ALS) and how microbiome profiling and gut-derived biomarkers are promising avenues for earlier detection...
Exclusive interview in Pharmaceutiques with Jean Pascal Zambaux, CEO, who explains how PLL Therapeutics is revolutionizing ALS care with an early-stage blood test (92% sensitivity) to detect the disease before symptoms appear, and a therapy targeting dysbiosis via the gut-brain axis. The challenge: to intervene...
Stage one results from PLL Therapeutics’ first-in-human, multi-stage phase I/II trial show favorable safety and tolerability of PLL001 in 12 ALS patients. Australian multi-stage study tested single ascending subcutaneous doses of PLL001 – in three dose cohorts - with placebo control....
Expansion in Asia-Pacific with second subsidiary, following Australia, pivotal to enrolling patients in phase II trial targeting ALS, a motor neuron disease with no cure....
Talk will highlight for investors role of PLL Therapeutics’ poly-L-Lysine-based therapy in helping combat neurodegenerative disorders and in early-stage and companion biomarkers....
Preeminent researcher in Amyotropic Lateral Sclerosis (ALS), Dr. Corcia heightens expertise behind PLL Therapeutics’ polypeptide delivery platform and development of world’s first blood biomarker to detect early onset of ALS...
Multi-stage Australian study will evaluate safety of PLL001 in 12 ALS patients, testing three different doses along with placebo...
Australia’s Human Research Ethics Committees (HREC) cleared first-in-human study of drug candidate PLL001. PLL001 aims at restoring microbiome and stopping gut from leaking to treat root cause of ALS, not solely symptoms...
The intestine is well known to be our second brain and nearly 500 million neurons line our intestine (20 times less than our brain). But in the history of humanity was not the intestine our first Brain? The first primitive organisms were a simple digestive...